De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!
Carl Zeiss Meditec Beheer
Beheer criteriumcontroles 4/4
Momenteel beschikken wij niet over voldoende informatie over de CEO.
Belangrijke informatie
Markus Weber
Algemeen directeur
€1.1m
Totale compensatie
| Percentage CEO-salaris | 40.5% |
| Dienstverband CEO | 2.8yrs |
| Eigendom CEO | n/a |
| Management gemiddelde ambtstermijn | 4.5yrs |
| Gemiddelde ambtstermijn bestuur | 3.4yrs |
Recente managementupdates
Here's Why We Think Carl Zeiss Meditec AG's (ETR:AFX) CEO Compensation Looks Fair for the time being
May 21
How Should Investors Feel About Carl Zeiss Meditec's (ETR:AFX) CEO Remuneration?
Feb 16
Recent updates
Some Investors May Be Worried About Carl Zeiss Meditec's (ETR:AFX) Returns On Capital
Sep 19Does Carl Zeiss Meditec (ETR:AFX) Have A Healthy Balance Sheet?
Sep 06Are Investors Undervaluing Carl Zeiss Meditec AG (ETR:AFX) By 27%?
Aug 23At €62.50, Is It Time To Put Carl Zeiss Meditec AG (ETR:AFX) On Your Watch List?
Aug 09Carl Zeiss Meditec AG's (ETR:AFX) 25% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/ERatio
Jul 11Returns On Capital At Carl Zeiss Meditec (ETR:AFX) Have Stalled
Jun 10Carl Zeiss Meditec AG's (ETR:AFX) Popularity With Investors Is Under Threat From Overpricing
May 26Carl Zeiss Meditec AG Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
May 11Calculating The Fair Value Of Carl Zeiss Meditec AG (ETR:AFX)
May 09Is There Now An Opportunity In Carl Zeiss Meditec AG (ETR:AFX)?
Mar 24Does Carl Zeiss Meditec (ETR:AFX) Have A Healthy Balance Sheet?
Mar 11Slowing Rates Of Return At Carl Zeiss Meditec (ETR:AFX) Leave Little Room For Excitement
Feb 12Calculating The Fair Value Of Carl Zeiss Meditec AG (ETR:AFX)
Jan 29What Does Carl Zeiss Meditec AG's (ETR:AFX) Share Price Indicate?
Dec 08Carl Zeiss Meditec (ETR:AFX) Is Experiencing Growth In Returns On Capital
Nov 08Carl Zeiss Meditec AG's (ETR:AFX) Intrinsic Value Is Potentially 37% Above Its Share Price
Oct 24Is Carl Zeiss Meditec (ETR:AFX) A Risky Investment?
Sep 24Should You Investigate Carl Zeiss Meditec AG (ETR:AFX) At €85.72?
Sep 08Calculating The Fair Value Of Carl Zeiss Meditec AG (ETR:AFX)
Jul 24We Like These Underlying Return On Capital Trends At Carl Zeiss Meditec (ETR:AFX)
Jun 19Should You Think About Buying Carl Zeiss Meditec AG (ETR:AFX) Now?
Jun 06Is Now The Time To Put Carl Zeiss Meditec (ETR:AFX) On Your Watchlist?
May 22Carl Zeiss Meditec AG's (ETR:AFX) Intrinsic Value Is Potentially 24% Below Its Share Price
Apr 19Carl Zeiss Meditec (ETR:AFX) Has A Pretty Healthy Balance Sheet
Feb 26Carl Zeiss Meditec's (ETR:AFX) Shareholders Will Receive A Bigger Dividend Than Last Year
Feb 10Here's Why We Think Carl Zeiss Meditec (ETR:AFX) Is Well Worth Watching
Jan 28Carl Zeiss Meditec (ETR:AFX) Has Announced That It Will Be Increasing Its Dividend To €1.10
Jan 12Carl Zeiss Meditec (ETR:AFX) Will Pay A Larger Dividend Than Last Year At €1.10
Dec 29Carl Zeiss Meditec (ETR:AFX) Has Announced That It Will Be Increasing Its Dividend To €1.10
Dec 14What Is Carl Zeiss Meditec AG's (ETR:AFX) Share Price Doing?
Nov 04Calculating The Intrinsic Value Of Carl Zeiss Meditec AG (ETR:AFX)
Oct 18Investors Will Want Carl Zeiss Meditec's (ETR:AFX) Growth In ROCE To Persist
Sep 12Carl Zeiss Meditec (ETR:AFX) Seems To Use Debt Rather Sparingly
Aug 25Returns On Capital At Carl Zeiss Meditec (ETR:AFX) Have Hit The Brakes
May 30Does Carl Zeiss Meditec (ETR:AFX) Have A Healthy Balance Sheet?
Feb 27Carl Zeiss Meditec's (ETR:AFX) Returns Have Hit A Wall
Feb 08Here's Why We Think Carl Zeiss Meditec (ETR:AFX) Is Well Worth Watching
Dec 12Carl Zeiss Meditec (ETR:AFX) Has Some Way To Go To Become A Multi-Bagger
Nov 06If You Like EPS Growth Then Check Out Carl Zeiss Meditec (ETR:AFX) Before It's Too Late
Sep 06Investors Met With Slowing Returns on Capital At Carl Zeiss Meditec (ETR:AFX)
Aug 08Here's Why We Think Carl Zeiss Meditec AG's (ETR:AFX) CEO Compensation Looks Fair for the time being
May 21Why Carl Zeiss Meditec's (ETR:AFX) Shaky Earnings Are Just The Beginning Of Its Problems
May 18Capital Allocation Trends At Carl Zeiss Meditec (ETR:AFX) Aren't Ideal
Apr 28Carl Zeiss Meditec AG's (ETR:AFX) Intrinsic Value Is Potentially 19% Below Its Share Price
Mar 09How Should Investors Feel About Carl Zeiss Meditec's (ETR:AFX) CEO Remuneration?
Feb 16Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | €203m |
| Mar 31 2024 | n/a | n/a | €261m |
| Dec 31 2023 | n/a | n/a | €277m |
| Sep 30 2023 | €1m | €426k | €290m |
| Jun 30 2023 | n/a | n/a | €308m |
| Mar 31 2023 | n/a | n/a | €278m |
| Dec 31 2022 | n/a | n/a | €307m |
| Sep 30 2022 | €1m | €298k | €294m |
Compensatie versus markt: De totale vergoeding ($USD 1.16M ) Markus } ligt onder het gemiddelde voor bedrijven van vergelijkbare omvang in de German markt ($USD 3.18M ).
Compensatie versus inkomsten: De vergoeding van Markus is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.
CEO
Markus Weber
2.8yrs
Tenure
€1,050,400
Compensatie
Dr. Markus Weber is CEO & Chairman of Management Board of Carl Zeiss Meditec AG from January 01, 2022 and served as its President since January 01, 2022 until December 2022. He joined ZEISS Semiconductor M...
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| CEO & Chairman of Management Board | 2.8yrs | €1.05m | geen gegevens | |
| CFO & Member of the Management Board | 6yrs | €799.30k | geen gegevens | |
| Head of Global Regulatory & Clinical Affairs | 1.8yrs | geen gegevens | geen gegevens | |
| Chief Operating Officer | no data | geen gegevens | geen gegevens | |
| Director of Investor Relations | no data | geen gegevens | geen gegevens | |
| Chief Human Resources Officer | no data | geen gegevens | geen gegevens | |
| Chief Medical Officer for Global Ophthalmic Devices | 8yrs | geen gegevens | geen gegevens | |
| Head of Sales for Ophthalmic Devices & President of Carl Zeiss Meditec | 4.6yrs | geen gegevens | geen gegevens | |
| President of Ophthalmic Devices and Head of the Ophthalmic Devices Strategic & Digital Business Unit | 4.4yrs | geen gegevens | geen gegevens | |
| Head of the Microsurgery Strategic Business Unit - ZEISS Medical Technology | no data | geen gegevens | geen gegevens |
4.5yrs
Gemiddelde duur
59yo
Gemiddelde leeftijd
Ervaren management: Het managementteam van AFX wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.5 jaar).
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Head of Global Regulatory & Clinical Affairs | 1.6yrs | geen gegevens | geen gegevens | |
| Chairman of the Supervisory Board | 4.3yrs | geen gegevens | geen gegevens | |
| Honorary Chairman of the Supervisory Board | 3.4yrs | €43.10k | geen gegevens | |
| Member of the Supervisory Board | 4.3yrs | €36.00k | geen gegevens | |
| Member of the Supervisory Board | 3.4yrs | €55.00k | geen gegevens | |
| Employee Representative Member of the Supervisory Board | 1.6yrs | geen gegevens | geen gegevens | |
| Member of the Supervisory Board | 6.5yrs | €52.00k | geen gegevens | |
| Employee Representative Deputy Chairman of Supervisory Board | 5yrs | €40.50k | geen gegevens | |
| Employee Representative Member of Supervisory Board | 4.6yrs | €36.00k | geen gegevens | |
| Member of Supervisory Board | 3.4yrs | geen gegevens | geen gegevens | |
| Employee Representative Member of the Supervisory Board | 2.6yrs | €19.20k | geen gegevens | |
| Employee Representative Member of the Supervisory Board | 1.6yrs | geen gegevens | geen gegevens |
3.4yrs
Gemiddelde duur
53yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van AFX wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.4 jaar).